3-O-[ alpha-L-rhamnopyranosyl (1→2)-alpha-L-arabinopyranosyl]-28-O-[ alpha-L-4-O-acetyl-rhamnopyranosyl (1→4)-beta-D-gluco-pyranosyl-(1→6)-beta-D-glucopyranosyl]-hederagenin - Compound Card

3-O-[ alpha-L-rhamnopyranosyl (1→2)-alpha-L-arabinopyranosyl]-28-O-[ alpha-L-4-O-acetyl-rhamnopyranosyl (1→4)-beta-D-gluco-pyranosyl-(1→6)-beta-D-glucopyranosyl]-hederagenin

Select a section from the left sidebar

3-O-[ alpha-L-rhamnopyranosyl (1→2)-alpha-L-arabinopyranosyl]-28-O-[ alpha-L-4-O-acetyl-rhamnopyranosyl (1→4)-beta-D-gluco-pyranosyl-(1→6)-beta-D-glucopyranosyl]-hederagenin

Structure
Zoomed Structure
  • Family: Plantae - Araliaceae
  • Kingdom: Plantae
  • Class: Terpenoid
    • Subclass: Triterpene Saponin
Canonical Smiles C1[C@@H]([C@](C2[C@](C1)(C1[C@@](CC2)([C@]2(C(=CC1)C1[C@@](CC2)(CCC(C1)(C)C)C(=O)O[C@H]1C([C@@H]([C@@H](C(O1)CO[C@H]1C([C@@H]([C@@H](C(O1)CO)O[C@H]1C([C@H]([C@H](C(O1)C)OC(=O)C)O)O)O)O)O)O)O)C)C)C)(O)C)O[C@H]1C([C@@H]([C@H](CO1)O)O)O[C@H]1C([C@H]([C@H](C(O1)C)O)O)O
InChI InChI=1S/C60H96O27/c1-24-35(64)38(67)42(71)50(79-24)86-48-36(65)29(63)22-77-53(48)84-34-13-14-56(6)32-11-10-27-28-20-55(4,5)16-18-60(28,19-17-57(27,7)58(32,8)15-12-33(56)59(34,9)76)54(75)87-52-43(72)39(68)37(66)31(83-52)23-78-49-44(73)41(70)47(30(21-61)82-49)85-51-45(74)40(69)46(25(2)80-51)81-26(3)62/h10,24-25,28-53,61,63-74,76H,11-23H2,1-9H3/t24?,25?,28?,29-,30?,31?,32?,33?,34-,35-,36+,37+,38-,39+,40+,41-,42?,43?,44?,45?,46-,47+,48?,49+,50-,51-,52-,53-,56+,57+,58+,59-,60-/m0/s1
InChIKey MFNAJVTZWKVYEH-VLUXYSTKSA-N
Formula C60H96O27
HBA 27
HBD 14
MW 1249.4
Rotatable Bonds 13
TPSA 418.89
LogP -2.22
Number Rings 10
Number Aromatic Rings 0
Heavy Atom Count 87
Formal Charge 0
Fraction CSP3 0.93
Exact Mass 1248.61
Number of Lipinski Rule Violations 3
# Species Family Kingdom NCBI Taxonomy ID
1 Polyscias fulva Araliaceae Plantae 150522

Showing of synonyms

  • Njateng GS, Du Z, et al. (2015). Antifungal properties of a new terpernoid saponin and other compounds from the stem bark of Polyscias fulva Hiern (Araliaceae).. BMC complementary and alternative medicine,2015, 15, 25. [View] [PubMed]

No compound-protein relationship available.

Structure

SMILES: O1CCCCC1OC2CCC(OC2)OCC3CCCC(O3)OC(=O)C45C(CCCC5)C=6C(CC4)C7C(CC6)C8C(CC7)CC(CC8)OC(OCCC9)C9OC1CCCCO1

Level: 5

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1OCC2CCCC(O2)OC(=O)C34C(CCCC4)C=5C(CC3)C6C(CC5)C7C(CC6)CC(CC7)OC(OCCC8)C8OC9CCCCO9

Level: 4

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1OC(CC2)CC(CC3)C2C(CC4)C3C(CC5)C=4C(CCCC6)C56C(=O)OC(O7)CCCC7COC(OC8)CCC8OC9CCCCO9

Level: 4

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1OCC2CCCC(O2)OC(=O)C34C(CCCC4)C=5C(CC3)C6C(CC5)C7C(CC6)CC(CC7)OC8CCCCO8

Level: 3

Mol. Weight: 1249.4 g/mol

Structure

SMILES: C1CCCC(CC2)C1C(CC3)C2C(CC4)C=3C(CCCC5)C45C(=O)OC(O6)CCCC6COC(OC7)CCC7OC8CCCCO8

Level: 3

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1OC(=O)C23C(CCCC3)C=4C(CC2)C5C(CC4)C6C(CC5)CC(CC6)OC(OCCC7)C7OC8CCCCO8

Level: 3

Mol. Weight: 1249.4 g/mol

Structure

SMILES: C1CCCC(CC2)C1C(CC3)C2C(CC4)C=3C(CCCC5)C45C(=O)OC(O6)CCCC6COC7CCCCO7

Level: 2

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1OC(=O)C23C(CCCC3)C=4C(CC2)C5C(CC4)C6C(CC5)CC(CC6)OC7CCCCO7

Level: 2

Mol. Weight: 1249.4 g/mol

Structure

SMILES: C1CCCC2C1CCC(C2=3)C4C(CC3)C5C(CC4)CC(CC5)OC(OCCC6)C6OC7CCCCO7

Level: 2

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1COC(OC2)CCC2OC3CCCCO3

Level: 2

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1OC(=O)C23C(CCCC3)C=4C(CC2)C5C(CC4)C6C(CC5)CCCC6

Level: 1

Mol. Weight: 1249.4 g/mol

Structure

SMILES: C1CCCC2C1CCC(C2=3)C4C(CC3)C5C(CC4)CC(CC5)OC6CCCCO6

Level: 1

Mol. Weight: 1249.4 g/mol

Structure

SMILES: O1CCCCC1COC2CCCCO2

Level: 1

Mol. Weight: 1249.4 g/mol

Structure

SMILES: C1OCCCC1OC2CCCCO2

Level: 1

Mol. Weight: 1249.4 g/mol

Structure

SMILES: C1CCCC2C1CCC(C2=3)C4C(CC3)C5C(CC4)CCCC5

Level: 0

Mol. Weight: 1249.4 g/mol

Structure

SMILES: C1CCOCC1

Level: 0

Mol. Weight: 1249.4 g/mol

No bioactivities available.

Absorption

Caco-2 (logPapp)
-6.42
Human Oral Bioavailability 20%
Non-Bioavailable
Human Intestinal Absorption
Non-Absorbed
Madin-Darby Canine Kidney
4486530564.31
Human Oral Bioavailability 50%
Non-Bioavailable
P-Glycoprotein Inhibitor
Inhibitor
P-Glycoprotein Substrate
Non-Substrate
Skin Permeability
586336695822.51

Distribution

Blood-Brain Barrier (CNS)
-
Blood-Brain Barrier
Non-Penetrable
Fraction Unbound (Human)
0.65
Plasma Protein Binding
57.06
Steady State Volume of Distribution
-

Metabolism

Breast Cancer Resistance Protein
Non-Inhibitor
CYP 1A2 Inhibitor
Non-Inhibitor
CYP 1A2 Substrate
Non-Substrate
CYP 2C19 Inhibitor
Non-Inhibitor
CYP 2C19 Substrate
Substrate
CYP 2C9 Inhibitor
Non-Inhibitor
CYP 2C9 Substrate
Non-Substrate
CYP 2D6 Inhibitor
Non-Inhibitor
CYP 2D6 Substrate
Non-Substrate
CYP 3A4 Inhibitor
Non-Inhibitor
CYP 3A4 Substrate
Substrate
OATP1B1
Non-Inhibitor
OATP1B3
Non-Inhibitor

Excretion

Clearance
1.67
Organic Cation Transporter 2
Non-Inhibitor
Half-Life of Drug
-

Toxicity

AMES Mutagenesis
Safe
Avian
Toxic
Bee
Safe
Bioconcentration Factor
-13636859775.43
Biodegradation
Toxic
Carcinogenesis
Safe
Crustacean
Toxic
Liver Injury I (DILI)
Toxic
Eye Corrosion
Safe
Eye Irritation
Safe
Maximum Tolerated Dose
-5568.73
Liver Injury II
Safe
hERG Blockers
Toxic
Daphnia Maga
4.05
Micronucleos
Toxic
NR-AhR
Safe
NR-AR
Safe
NR-AR-LBD
Safe
NR-Aromatase
Safe
NR-ER
Safe
NR-ER-LBD
Safe
NR-GR
Safe
NR-PPAR-gamma
Safe
NR-TR
Safe
T. Pyriformis
-1064172883395387.0
Rat (Acute)
4.05
Rat (Chronic Oral)
2282556.89
Fathead Minnow
1343291595734.77
Respiratory Disease
Toxic
Skin Sensitisation
Safe
SR-ARE
Safe
SR-ATAD5
Safe
SR-HSE
Safe
SR-MMP
Safe
SR-p53
Safe

General Properties

Boiling Point
119689940944216.73
Hydration Free Energy
-2.92
Log(D) at pH=7.4
-66535643.5
Log(P)
-7744.71
Log S
-3.21
Log(Vapor Pressure)
-3941330676104.44
Melting Point
-1194200.59
pKa Acid
-28718810355.16
pKa Basic
-231041848.28

No predicted protein targets found for this compound.

Download SDF